Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Prenatal treatment normalizes brain development in Down syndrome model

Oct. 27, 2020

IND clearance paves way for phase II study of BXCL-501 for agitation associated with delirium

Oct. 27, 2020

Anelixis begins phase IIa study of AT-1501 in ALS

Oct. 26, 2020

Ultragenyx and Solid Biosciences collaborate to develop new gene therapies for DMD

Oct. 26, 2020

FDA issues complete response letter for Qtrypta

Oct. 23, 2020

Ionis initiates phase I/II study of ION-541 to treat broad ALS population

Oct. 23, 2020

Targeting periphery could be viable approach in ALS

Oct. 23, 2020

Nanoform targets initiation of first-in-human trial of nanoformed piroxicam before year-end

Oct. 22, 2020

Oxeia initiates phase II study of OXE-103 for concussions

Oct. 22, 2020

Optimization of selective antagonists of vasopressin V1A receptor derived from triazolobenzazepines

Oct. 22, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 21, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
WHO declares Ebola outbreak a public health emergency of international concern
BioWorld
The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...
Nxera Pharma prepares and tests new GPR17 antagonists
BioWorld Science
Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...